Citeline signs Gold Patron agreement with SwedenBIO
Citeline and SwedenBIO increase cooperation through a new agreement.
Citeline and SwedenBIO increase cooperation through a new agreement.
Welcome to two panel discussions on important and topical issues with knowledgeable and insightful participants.
You are social, business-driven and curious with a heart that beats for new innovations and companies active in Life Science. Become our new Community Manager!
After one term as an ordinary board member, Anders Persson took over the chairmanship of SwedenBIO in May this year. We asked Anders a few questions about SwedenBIO and the development of the industry.
New chairman and two new board members to the SwedenBIO board.
Here are the documents for this year's General Assembly on May 14 in Stockholm.
SwedenBIO has initiated a series of activities to influence and support the training of the next generation talents.
SwedenBIO is one of the parties behind a feasibility study on a Swedish partnership for clinical trials that has been granted funding by Vinnova.
On September 18-19, SwedenBIO opens the doors to the eleventh edition of NLSDays - the largest life science event in the Nordic region.
How to create sustainable trading on the stock exchange
The life science sector is one of the strongest for listed small companies in Sweden. At the same time, the competition in the sector is fierce and it is necessary to work with the issues that affect share trading. A well-functioning share trading is important for creating growth in small and medium-sized companies.
Offer to you as an incubator company
Life for startup companies was not without challenges before the effects of the corona crisis hit, and the situation is now tough for many smaller companies. Now we want to contribute to building Sweden’s next generation of life science companies strong, for future export revenue and innovation power. Startup companies with up to four employees must be members of SwedenBIO for an annual fee of SEK 1,000.
Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection between innovation, capital and health. In the first part, we meet Adam Kostyal, European head of listing at Nasdaq, who looks at how the stock market year looked for the sector, talks about the impact of the pandemic and shares his predictions for the future.